

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Brown et al.
Serial No. : Not Yet Assigned
Filed : Simultaneously Herewith
For : DERMATOLOGICAL COMPOSITIONS AND
METHODS

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR §1.56 and 37 CFR §1.97(b)(1), applicants wish to call the Examiner's attention to the references listed on the Modified 1449 Form submitted herewith.

Pursuant to 37 CFR §1.98(d), copies of the references on the 1449 form are not being submitted herewith since each of the references was previously cited by or submitted to the Patent Office in prior application Serial No. 09/085,917, filed on May 28, 1998, from which this application claims priority under 35 U.S.C. §120. However, if for any reason, the Examiner believes it is necessary or desirable for applicants to provide copies of all or some of these references, the Examiner is requested to advise the undersigned attorney and any copies required will be provided.

The Examiner is respectfully requested to initial a copy of the Modified 1449 Form and return it to applicants to indicate consideration of the references listed thereon in connection with the prosecution of this application.

Date: 9/22/03

Respectfully submitted,

Maurice M. Klee

Maurice M. Klee, Ph.D.

Reg. No. 30,399

Attorney for Applicant

1951 Burr Street

Fairfield, CT 06824

(203) 255-1400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : David A. Brown, Alexander A. Khorlin, Krystyna Lesiak
and Wu Yun Ren
Serial No. : Not Yet Assigned
Filed : Simultaneously Herewith
For : DERMATOLOGICAL COMPOSITIONS AND
METHODS

MODIFIED 1449 FORMU.S. PATENT DOCUMENTS

<u>Examiner Initial</u>		<u>Document Number</u>	<u>Issue Date</u>	<u>Name</u>
_____	1.	3,956,361	5/1976	Stephen
_____	2.	4,102,995	7/1978	Hebborn
_____	3.	4,104,203	8/1978	Hall et al.
_____	4.	4,390,532	6/1983	Stüttgen et al.
_____	5.	4,528,126	7/1985	Bruns et al.
_____	6.	4,647,585	3/1987	Loots et al.
_____	7.	5,041,485	8/1991	Eichenauer et al.
_____	8.	5,068,453	11/1991	Kuwahara et al.
_____	9.	5,130,136	7/1992	Shono et al.
_____	10.	5,232,688	8/1993	Ziegler et al.
_____	11.	5,302,378	4/1994	Crotty et al.
_____	12.	5,352,440	10/1994	Gilchrest et al.
_____	13.	5,414,019	5/1995	Gould et al.

_____	14.	5,532,001	7/1996	Gilchrest et al.
_____	15.	5,554,359	9/1996	Fuller
_____	16.	5,574,195	11/1996	Chastain et al.
_____	17.	5,587,402	12/1996	Gould et al.
_____	18.	5,591,423	1/1997	Fuller
_____	19.	5,602,184	2/1997	Myers et al.
_____	20.	5,626,839	5/1997	Scales-Medeiros
_____	21.	5,698,184	12/1997	Pickart
_____	22.	5,700,450	12/1997	Gilchrest et al.
_____	23.	5,990,177	11/1999	Brown
_____	24.	6,214,888 B1	4/2001	Ren et al.
_____	25.	6,231,837 B1	5/2001	Stroud et al.
_____	26.	6,267,948 B1	7/2001	Ren et al.
_____	27.	6,294,585 B1	9/2001	Brown

FOREIGN PATENT DOCUMENTS

<u>Examiner Initial</u>		<u>Document Number</u>	<u>Date</u>	<u>Country</u>
_____	28.	0 643 113	3/1995	EP
_____	29.	1 200 862	8/1970	GB
_____	30.	WO 87 04617	7/1987	PCT
_____	31.	WO 89 00853	2/1989	PCT

_____	32.	WO 96 09810	4/1996	PCT
_____	33.	WO 96/26711	9/1996	PCT
_____	34.	WO 97 03170	1/1997	PCT
_____	35.	WO 97 30692	8/1997	PCT
_____	36.	WO 98 55085	12/1998	PCT
_____	37.	WO 98/11882	3/1998	PCT
_____	38.	WO 99 08654	2/1999	PCT

OTHER ART

Examiner
Initial

_____	39.	Abdel-Malek et al., "Mitogenic, Melanogenic, and cAMP Responses of Cultured Neonatal Human Melanocytes to Commonly Used Mitogens," <u>J. Cell. Physiol.</u> , 1992, 150:416-425.
_____	40.	Allan et al., "Topically Applied Diacylglycerols Increase Pigmentation in Guinea Pig Skin," <u>J. Invest. Dermatol.</u> , 1995, 105:687-692.
_____	41.	Barthelman et al., "Inhibitory Effects of Perillyl Alcohol on UVB-induced Murine Skin Cancer and AP-1 Transactivation," <u>Cancer Research</u> , 1998, 58:711-716.
_____	42.	Baudouin et al., "Constitutive Nitric Oxide Synthase Is Present in Normal Human Keratinocytes," <u>J. Invest. Dermatol.</u> , 1996, 106:428-431.
_____	43.	Bradford, M. "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," <u>Anal. Biochem.</u> , 1967, 72:248-254.

- _____ 44. Brown et al., "Aliphatic and Alicyclic Diols Induce Melanogenesis in Cultured Cells and Guinea Pig Skin," Journal of Investigative Dermatology, 1998, 110:428-437.

- _____ 45. Buchbauer et al., "Norbornanaverbindungen in der pharmazeutischen Forschung," Pharmazie, 1991, 46(Teil 1):88-97, and 46(Teil 2):116-170.

- _____ 46. Buchbauer et al., "Syntheses in the isocamphane series," Chemical Abstracts, Vol. 95, No. 115756e, 1981.

- _____ 47. Carsberg et al., "Ultraviolet radiation-induced melanogenesis in human melanocytes," J. Cell. Sci., 1994, 107:2591-2597.

- _____ 48. Chijiwa et al., "Inhibition of Forskolin-induced Neurite Outgrowth and Protein Phosphorylation by a Newly Synthesized Selective Inhibitor of Cyclic AMP-dependent Protein Kinase, *N*-[2-(*p*-Bromocinnamyl-amino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D Pheochromocytoma Cells," J. Biol. Chem., 1990, 265:5267-5272.

- _____ 49. Cieszka et al., "Growth and pigmentation in genetically related Cloudman S91 melanoma cell lines treated with 3-isobutyl-1-methyl-xanthine and β -melanocyte-stimulating hormone," Exp. Dermatol., 1995, 4:192-198.

- _____ 50. Crowell et al., "Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of *d*-limonene," Carcinogenesis, 1992, 13:1261-1264.

- _____ 51. Crowell et al., "Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation," Biochemical Pharmacology, 1994, 47:1405-1415.

- _____ 52. Eller et al., "DNA damage enhances melanogenesis," Proc. Natl. Acad. Sci., 1996, 93:1087-1092.
- _____ 53. Friedmann et al., "Ultraviolet Radiation Directly Induces Pigment Production by Cultured Human Melanocytes," J. Cell. Physiol., 1987, 133:88-94.
- _____ 54. Fuller et al., "Hormonal Regulation of Melanogenesis in Mouse Melanoma and in Human Melanocytes," Ann. NY Acad. Sci., 1993, 690:302-319.
- _____ 55. Fuller et al., "Regulation of Tyrosinase in Mouse Melanoma Cells and in Human Melanocytes by PKC and PKA Pathways," Pigment Cell Res., 26th International Pigment Cell Conference Abstracts, 1996, S5:65.
- _____ 56. Garvey et al., "Potent and Selective Inhibition of Human Nitric Oxide Synthases," J. Biol. Chem., 1994, 269:26669-26676.
- _____ 57. Gates et al., "Comparison of skin color with melanin content," J. Invest. Dermatol., 1953, 21:339-348.
- _____ 58. Gilchrest et al., "Mechanisms of Ultraviolet Light-Induced Pigmentation," Photochem. Photobiol., 1996, 63:1-10.
- _____ 59. Haag et al., "Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene," Cancer Chemotherapy and Pharmacology, 1994, 34:477-483.
- _____ 60. Hasenfratz "Experience in the treatment of acne vulgaris with the preparation acne-medice," Asthetische Medizin, 15:206-208, 1966.
- _____ 61. He et al., "Isoprenoids Suppress the Growth of Murine B16 Melanomas In Vitro and In Vivo," J. Nutr., 1997, 127:668-674.

- _____ 62. Hidaka et al., "Isoquinolinesulfonamides, Novel and Potent Inhibitors of Cyclic Nucleotide Dependent Protein Kinase and Protein Kinase C," Biochemistry, 1984, 23, 5036-5041.
- _____ 63. Introduction to the Cellular and Molecular Biology of Cancer, L. M. Franks and N. Teich, 1987, Oxford University Press.
- _____ 64. Ishida et al., "Biotransformation of terpenoids in mammals," Chemical Abstracts, Volume 93, #89860w, 1980.
- _____ 65. Jager et al., "Investigation of cytotoxic effects of 8 norbornane derivatives on 4 human cancer cell lines using the MTT assay," Pharmazie, 1995, 50:619-621.
- _____ 66. Jara et al., "Assays for Mammalian Tyrosinase: A Comparative Study," Pigment Cell Res., 1988, 1:332-339.
- _____ 67. Jimbow et al., "Biology of Melanocytes," in Dermatology in General Medicine, 4th edition, eds: Fitzpatrick et al., McGraw-Hill, New York, 1993, volume 1, pages 261-289.
- _____ 68. Kamikubo et al., "Preparation of (+)-tricycloen-3-one and its conversion into (+)-epi- β -santalene," Chemical Abstracts, Volume 122, No. 265669u, 1994.
- _____ 69. Karg et al., "Hydrogen Peroxide as a Mediator of Dopac-Induced Effects on Melanoma Cells," J. Invest. Dermatol., 1991, 96:224-227.
- _____ 70. Karg et al., "Hydrogen Peroxide as an Inducer of Elevated Tyrosinase Level in Melanoma Cells," J. Invest. Dermatol., 1993, 100:209S-213S.
- _____ 71. Karg et al., "Stimulation of Tyrosinase by Dihydroxy Phenyl Derivatives," Acta Derm. Venereol., 1989, 69:521-524.

- _____ 72. Karlberg et al., "Hydroperoxides in oxidized *d*-limonene identified as potent contact allergens," Arch. Dermatol. Res., 1994, 286:97-103.
- _____ 73. Kitahara et al., "Evaluation of Skin Damage of Cyclic Monoterpenes, Percutaneous Absorption Enhancers, by Using Cultured Human Skin Cells," Biol. Pharm. Bull., 1993, 16:912-916.
- _____ 74. Koval'skaya et al., "Determination of the spatial structure of mono- and bicyclic terpene derivatives on the base of nuclear magnetic resonance spectroscopy data," Chemical Abstracts, Volume 125, No. 276201y, 1996.
- _____ 75. Kozlov et al, "Camphene in the synthesis oxygen- and nitrogen-containing bicyclic derivatives," Chemical Abstracts, Volume 120, No. 77469p, 1994.
- _____ 76. Laukharanta et al., "Changes in Three-Dimensional Structure of Cultured S91 Mouse Melanoma Cells Associated with Growth Inhibition and Induction of Melanogenesis by Retinoids," Arch. Dermatol. Res., 1985, 277:147-150.
- _____ 77. McLane et al., "Phosphorylated Isomers of L-dopa Stimulate MSH Binding Capacity and Responsiveness to MSH in Cultured Melanoma Cells," Biochem. Biophys. Res. Commun., 1987, 145:719-725.
- _____ 78. Merkel, D. "10-Methylenetricyclene," Chemical Abstracts, Volume 66, No. 94723a, 1967.
- _____ 79. Miftakhov et al., "Prostanoids," Chemical Abstracts, Volume 121, No. 157329d, 1994.
- _____ 80. Miles et al., "Fluorometric Determination of Nitric Oxide," Methods, 1995, 7:40-47.

- _____ 81. Moshage et al., "Nitrite and Nitrate Determinations in Plasma: A Critical Evaluation," Clin. Chem., 1995, 41:892-896.
- _____ 82. Ohmori et al., "Pharmacological Regulation on Melanogenesis," Nippon Koshohin Kagakkaishi, 1994, 18:215-219. English translation attached¹.
- _____ 83. Orlow et al., "Inhibition of Induced Melanogenesis in Cloudman Melanoma Cells by Four Phenotypic Modifiers," Exp. Cell Res., 1990, 191:209-218.
- _____ 84. Pomerantz, S. H., "The Tyrosine Hydroxylase Activity of Mammalian Tyrosinase," J. Biol. Chem., 1966, 241:161-168.
- _____ 85. Romero et al., "Involvement of Nitric Oxide and Cyclic GMP in Melanogenesis of Human Melanocytes," J. Invest. Dermatol., 1996, 106:886.
- _____ 86. Romero et al., "Retinoic acid as modulator of UVB-induced melanocyte differentiation," J. Cell Sci., 1994, 107:1095-1103, .
- _____ 87. Romero-Graillet et al., "Nitric Oxide Produced by Ultraviolet-irradiated Keratinocytes Stimulates Melanogenesis," J. Clin. Invest., 1997, 99:635-642.
- _____ 88. Romero-Graillet et al., "Ultraviolet B Radiation Acts through the Nitric Oxide and cGMP Signal Transduction Pathway to Stimulate Melanogenesis in Human Melanocytes," J. Biol. Chem. 1996, 271:28052-28056.
- _____ 89. Russin et al., "Inhibition of rat mammary carcinogenesis by monoterpenoids," Carcinogenesis, 1989, 10:2161-2164.

¹ This English translation was provided to the prior assignee of this application by a competitor. Applicant has not made an independent translation and does not know whether this translation is accurate or not.

- _____ 90. Schmidt et al., "Determination of Nitric Oxide via Measurement of Nitrite and Nitrate in Culture Media," 1995, Biochemica 2:22.
- _____ 91. Shi et al., "Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol," Cancer Letters 95, 1995, 1-6.
- _____ 92. Shoff et al., "Concentration-dependent Increase of Murine P388 and B16 Population Doubling Time by the Acyclic Monoterpene Geraniol," Cancer Research, 1991, 41:37-42
- _____ 93. Siracký et al., "Relationship between melanogenesis, proliferative activity and response to chemotherapy of human melanoma xenografts," Neoplasia, 1984, 31:545-549, .
- _____ 94. Southan et al., "Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity," Br. J. Pharmacol., 1995, 114:510-516.
- _____ 95. Toullec et al., "The Bisinodylmaleimide GF 109203X is a Potent and Selective Inhibitor of Protein Kinase C," J. Biol. Chem., 1991, 266:15771-15781.
- _____ 96. Uçar, K., "The effects of histamine H2 receptor antagonists on melanogenesis and cellular proliferation in melanoma cells in culture," Biochem. Biophys. Res. Commun., 1991, 177:545-550 .
- _____ 97. Uchida et al., "Electrochemical oxidation of polycyclic cyclopropanes and camphene," Chemical Abstracts, Volume 112, No. 198816t, 1990.
- _____ 98. Wintzen et al., "Proopiomelanocortin, Its Derived Peptides, and the Skin," J. Invest. Dermatol., 1996, 106:3-10.